It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention. Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Since then, Sanford C. Bernstein, Raymond James, Stifel Nicolaus, and Barclays have all raised their price targets on the healthcare conglomerate.
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (NYSE: ABT) reported its full-year and fourth-quarter results for 2022 on Wednesday. Abbott's bad news definitely jumped out. While Abbott's sales fell 12% on a reported basis, the year-over-year decline was only 6.1% excluding the impact of foreign exchange.